Pfizer Stock Is A Race Between New Drugs And Old Patents

The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.

Pfizer (PFE) stock has returned 20.5% over the past twelve months and trades right at the top of its 52-week range, a strange place for a company whose revenue has not grown in a year. Obesity is not the near-term answer: management targets a first approval in 2028. The upside case is a race between Pfizer’s newly launched and acquired medicines and the looming patent expirations on its legacy blockbusters.

The Hole Shrank While The Replacement Grew

The patent cliff is the bear case, and it is shrinking. On the first-quarter 2026 call management sized the annual revenue its coming expirations will remove at $14 billion to $15 billion rather than $17 billion, after a settlement that delayed the loss of exclusivity on Vyndamax instead of accelerating it. Against that sit the launched and acquired products: Padcev in bladder cancer, NURTEC in migraine, and the legacy Seagen portfolio. They delivered $3.1 billion of revenue in the first quarter of 2026 and $3.2 billion in the second quarter, up 18% operationally. Annualized, that quarterly run rate puts the portfolio on a pace exceeding $12 billion. Management sets that against the expirations and calls the gap manageable; on $63.7 billion of trailing revenue, though, the launched and acquired portfolio is a bridge, not a step change.

A COVID Shortfall Absorbed, And The Revenue Midpoint Still Went Up

Pfizer cut its 2026 COVID revenue expectation to about $4 billion from $5 billion, because low incidence limits Paxlovid use. The company still raised the midpoint of full-year 2026 revenue guidance by $500 million, after lifting non-COVID guidance by $1.5 billion, led by Eliquis, Padcev and NURTEC, while adjusted EPS guidance was only reaffirmed. Cutting a billion dollars from the COVID line and lifting the revenue midpoint anyway is the transition in miniature.

Cost helps too: Pfizer’s cost improvement programs target roughly $9.7 billion in cumulative net savings through 2029. With the 2026 portion of those savings already factored into full-year guidance, the next leg of near-term growth has to come from revenue. The trailing twelve-month operating margin of 26.7% sits well above a 19.3% three-year average, while net margin contracted to 6.8% against a 9.1% three-year average due to one-off impairment charges. Stripping out non-cash noise, underlying operational efficiency that expands margins even during top-line transitions is the defensive trait the Trefis High Quality Portfolio targets.

Cost Savings Are Already In The Guidance, So Trials Decide

With the cost savings already in the guidance, the next leg has to come from revenue, and revenue means trials. The second quarter of 2026 showed what that costs: a failed Phase III readout in previously treated non-squamous non-small cell lung cancer and, to a lesser extent, the removal of Oxbryta from the forecast forced $4.3 billion of non-cash intangible impairments. Management’s aim of a risk-adjusted high single-digit revenue CAGR does not start until after 2028. The nearest test is the Phase III readout for mevrometostat with XTANDI in prostate cancer, which management expects in the fourth quarter of 2026. Until then the dividend is what pays you to wait, and management says it will be maintained. The prize is a re-rating, not a moonshot: PFE has cleared a 30% gain in under two months only twice since 2010—the first not until 2021. So before paying up at this level, it is worth seeing how much recovery the price already assumes.

Owning This Turnaround Means Owning Its Readouts

Much of the remaining upside in this case rides on binary trial results that either deliver or disappoint. A rules-based basket like the Trefis High Quality Portfolio spreads the same money across many outcomes, so no one readout decides the result. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.